These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 33950452)

  • 1. [Many patients with cystic fibrosis have a better quality of life now].
    Eschenhagen P; Schwarz C
    MMW Fortschr Med; 2021 Mar; 163(Suppl 1):74-81. PubMed ID: 33950452
    [No Abstract]   [Full Text] [Related]  

  • 2. Antioxidant supplementation for lung disease in cystic fibrosis.
    Ciofu O; Lykkesfeldt J
    Cochrane Database Syst Rev; 2014 Aug; (8):CD007020. PubMed ID: 25102015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled mannitol and cystic fibrosis. Unnecessary bronchial irritation.
    Prescrire Int; 2014 Apr; 23(148):89-91. PubMed ID: 24860889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled mannitol for cystic fibrosis.
    Nolan SJ; Thornton J; Murray CS; Dwyer T
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008649. PubMed ID: 26451533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients.
    Westerman EM; Heijerman HG; Frijlink HW
    Expert Opin Drug Deliv; 2007 Mar; 4(2):91-4. PubMed ID: 17335406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cystic fibrosis: current therapy. Inhalation therapy].
    Wildhaber J
    Schweiz Med Wochenschr Suppl; 2000; 122():40S-42S. PubMed ID: 12536471
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety, Tolerability, and Effects of Sodium Bicarbonate Inhalation in Cystic Fibrosis.
    Gomez CCS; Parazzi PLF; Clinckspoor KJ; Mauch RM; Pessine FBT; Levy CE; Peixoto AO; Ribeiro MÂGO; Ribeiro AF; Conrad D; Quinton PM; Marson FAL; Ribeiro JD
    Clin Drug Investig; 2020 Feb; 40(2):105-117. PubMed ID: 31721070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cystic fibrosis: current therapy. Inhalation antibiotics].
    Mordasini C
    Schweiz Med Wochenschr Suppl; 2000; 122():43S-44S. PubMed ID: 12536472
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cystic fibrosis: current therapy. Topical (inhalation) steroids].
    Schöni MH
    Schweiz Med Wochenschr Suppl; 2000; 122():45S-46S. PubMed ID: 12536473
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhaled hypertonic saline as a therapy for cystic fibrosis.
    Elkins MR; Bye PT
    Curr Opin Pulm Med; 2006 Nov; 12(6):445-52. PubMed ID: 17053496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements.
    Chuchalin A; Amelina E; Bianco F
    Pulm Pharmacol Ther; 2009 Dec; 22(6):526-32. PubMed ID: 19616111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation.
    Schechter MS; Trueman D; Farquharson R; Higuchi K; Daines CL
    Ann Am Thorac Soc; 2015 Jul; 12(7):1030-8. PubMed ID: 26053185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of dornase alfa inhalation for cystic fibrosis.
    Dentice R; Elkins M
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD007923. PubMed ID: 27457496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cystic fibrosis: current therapy. Inhalation therapy with recombinant DNAse].
    Rutishauser M
    Schweiz Med Wochenschr Suppl; 2000; 122():47S-48S. PubMed ID: 12536474
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.
    Stuart Elborn J; Geller DE; Conrad D; Aaron SD; Smyth AR; Fischer R; Kerem E; Bell SC; Loutit JS; Dudley MN; Morgan EE; VanDevanter DR; Flume PA
    J Cyst Fibros; 2015 Jul; 14(4):507-14. PubMed ID: 25592656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic Fibrosis Frequently Asked Questions: Question 4: What is the appropriate duration of therapy for respiratory exacerbations in Cystic Fibrosis patients infected with Pseudomonas aeruginosa?
    Sutton KM; Fitzgerald DA
    Paediatr Respir Rev; 2016 Jan; 17():60-2. PubMed ID: 25982382
    [No Abstract]   [Full Text] [Related]  

  • 17. Hypertonic saline inhalation in cystic fibrosis--salt in the wound, or sweet success?
    Enderby B; Doull I
    Arch Dis Child; 2007 Mar; 92(3):195-6. PubMed ID: 17337677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonantibiotic inhaled therapy in cystic fibrosis: new data.
    Lindemann H
    Pediatr Pulmonol Suppl; 1995; 11():70-1. PubMed ID: 7547355
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of aerosolized antibiotics in patients with cystic fibrosis.
    Saiman L
    Pediatr Infect Dis J; 1998 Feb; 17(2):158-9. PubMed ID: 9493815
    [No Abstract]   [Full Text] [Related]  

  • 20. Aztreonam for inhalation solution (Cayston) for cystic fibrosis.
    Med Lett Drugs Ther; 2010 Aug; 52(1344):63-4. PubMed ID: 20697341
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.